Skip to main content
Publications
Keens T, Hoffman V, Topuria I, Elder K, Cerf S, Mulder K, Roberts J, Lysinger J, Del Carmen Reyes M, Berdella M, Cairns AM, Jain M, Ganapathy V, Lou Y, Morcos B, Wu C, Sass L, VX19-CFD-003 Study Group. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis. Heliyon. 2024 Mar 26;10(7):e28508. doi: 10.1016/j.heliyon.2024.e28508
Handels RLH, Green C, Gustavsson A, Herring WL, Winblad B, Wimo A, Skoldunger A, Karlsson A, Anderson R, Belger M, Bruck C, Espinosa R, Hlavka J, Jutlowitz E, Lin P-J, Lopez Mendez M, Mar J, Shewmaker P, Spackman E, Tafozzoli A, Tysinger B, Jonsson L. Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge. Alzheimers Dement. 2023 May;19(5):1800-20. doi: 10.1002/alz.12811
Pavel M, Horsch D, Anthony L, Ervin C, Kulke MH, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D, Lapuerta P. Patient interviews in TELESTAR, a phase 3 study of telotristat etiprate, report meaningful improvement in carcinoid syndrome. Poster presented at the 2016 European Neuroendocrine Tumor Society (ENETS) Annual Meeting; March 2016. Barcelona, Spain. [abstract] Neuroendocrinology. 2016; 103:89.